Now showing items 1-8 of 8

    • Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. 

      Moreau, P; Dimopoulos, MA; Richardson, PG; Siegel, DS; Cavo, M; Corradini, P; Weisel, K; Delforge, M; O'Gorman, P; Song, K; Chen, C; Bahlis, N; Oriol, A; Hansson, M; Kaiser, M; Anttila, P; Raymakers, R; Joao, C; Cook, G; Sternas, L; Biyukov, T; Slaughter, A; Hong, K; Herring, J; Yu, X; Zaki, M; San-Miguel, J (2017-09)
      OBJECTIVES: Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough ...
    • Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. 

      Grever, MR; Abdel-Wahab, O; Andritsos, LA; Banerji, V; Barrientos, J; Blachly, JS; Call, TG; Catovsky, D; Dearden, C; Demeter, J; Else, M; Forconi, F; Gozzetti, A; Ho, AD; Johnston, JB; Jones, J; Juliusson, G; Kraut, E; Kreitman, RJ; Larratt, L; Lauria, F; Lozanski, G; Montserrat, E; Parikh, SA; Park, JH; Polliack, A; Quest, GR; Rai, KR; Ravandi, F; Robak, T; Saven, A; Seymour, JF; Tadmor, T; Tallman, MS; Tam, C; Tiacci, E; Troussard, X; Zent, CS; Zenz, T; Zinzani, PL; Falini, B (2017-02-02)
      Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high ...
    • Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. 

      Califano, R; Greystoke, A; Lal, R; Thompson, J; Popat, S (2017-09)
      Anaplastic lymphoma kinase rearrangement (ALK+) occurs in approximately 2-7% of patients with non-small cell lung cancer (NSCLC), contributing to a considerable number of patients with ALK+ NSCLC worldwide. Ceritinib is a ...
    • Management of stage I and II nonsmall cell lung cancer. 

      McDonald, F; De Waele, M; Hendriks, LEL; Faivre-Finn, C; Dingemans, A-MC; Van Schil, PE (2017-01)
      The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. ...
    • Novel therapeutic approaches in chondrosarcoma. 

      Polychronidou, G; Karavasilis, V; Pollack, SM; Huang, PH; Lee, A; Jones, RL (2017-03)
      Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally ...
    • Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. 

      Owen, C; Constantinidou, A; Miah, AB; Thway, K; Fisher, C; Benson, C; Zaidi, S; Messiou, C; VAN DER Graaf, WTA; Jones, RL (2018-09)
      BACKGROUND/AIM: Synovial sarcoma is a soft tissue sarcoma that tends to affect young adults. There are few reports on primary synovial sarcoma of the thyroid and the aim of this study was to document the clinical and ...
    • Systemic therapy in retroperitoneal sarcoma management. 

      Constantinidou, A; Jones, RL (2018-01)
      There is paucity of randomized controlled data on the role of systemic therapy in retroperitoneal sarcomas. The type of systemic therapy used is guided by the histological subtype. The majority of retroperitoneal sarcomas ...
    • Treatment of soft tissue sarcoma: a focus on earlier stages. 

      Gronchi, A; Maki, RG; Jones, RL (2017-01)
      Surgery, with or without radiation therapy, is the standard of care for primary soft tissue sarcoma, with adjuvant/neodjuvant chemotherapy playing a role only in high-risk patients. Chemotherapy is generally the principal ...